Background

Systemic lupus erythematosus (SLE) is an autoimmune-mediated, chronic inflammatory disease with variable clinical presentation, ranging from localised skin lesions to a destructive systemic disorder without cutaneous changes. Antibodies to double-stranded (ds) DNA are a well-known, specific marker for SLE with a prevalence from 50-90%, depending on disease severity. Their titre often correlates with disease activity and provides a tool for therapy control. Circulating DNA/anti-DNA immune complexes are considered to play a role in the pathogenesis of SLE. ds DNA-antibodies constitute a SLE criterion according to the American College of Rheumatology (ACR).

Technical information

The EULISA ds DNA IgG is intended for the quantitative or qualitative determination of IgG antibodies in human serum, directed against ds DNA. The immobilised antigen is a highly purified preparation of plasmid ds DNA (>90% in supercoiled state), free from chromosomal DNA and protein (histones). The test is fast (incubation time 30 / 30 / 30 minutes) and flexible (break apart wells, ready-to-use reagents). Six calibrators allow quantitative measurements; a negative and a positive control check the assay performance.